A randomized controlled trial for gualou danshen granules in the treatment of unstable angina pectoris patients with phlegm-blood stasis syndrome. Issue 33 (14th August 2020)

• Record Type: Journal Article
• Authors: Guo, Jianbo; Dai, Shuang; Ding, Yukun; He, Haoqiang; Zhang, Hui; Dan, Wenchao; Qin, Kun; Wang, Hui; Li, Anqi; Meng, Peipei; Li, Shangjin; He, Qingyong
• Is Part Of: Medicine. Volume 99:Issue 33(2020)
• Publication Date: 2020-08-14
• Subjects: Gualou Danshen granules -- phlegm-blood stasis syndrome -- unstable angina pectoris; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000021593
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Introduction: Unstable angina pectoris is an acute exacerbation secondary to coronary artery occlusion. In routine clinical treatment, patients with unstable angina pectoris are prone to recurrence or aggravation of symptoms. Based on the traditional Chinese medicine (TCM) theory, phlegm, and blood stasis are one of the main pathological factors of unstable angina pectoris. The treatment of unstable angina pectoris with phlegm-blood stasis syndrome by Gualou Danshen granules (GLDS) has been the focus of many clinical trials. However, there is no evidence to prove the safety or clinical efficacy of GLDS. Methods and analysis: In this study, we will conduct a 4-week randomized, controlled feasibility study, with participants recruited from Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine. Sixty subjects are to be diagnosed as having phlegm-blood stasis syndrome and randomly divided into a treatment group (GLDS) and placebo group in a 1:1 ratio. Result measurements will include therapeutic indicators (Clinical Symptom Rating Scale, Phlegm-Blood Stasis Syndrome Scale, and Seattle Angina Questionnaire) and safety indicators (blood routine, urine routine, electrocardiogram, liver function, and kidney function). The clinical data management system (http://www.tcmcec.net/ ) will be used to collect and manage data. Quality control will be implemented according to good clinical practice. Discussion: Previous TCM clinical trials have investigated if adding GLDS to standard routine treatment can improve the therapeutic effect in patients with unstable angina pectoris. This study focuses on the safety and efficacy of GLDS on unstable angina pectoris of phlegm-blood stasis type, in order to obtain relevant clinical evidence. Trial registration: This study is approved by the Ethics Committee of Guang'anmen Hospital of the China Academy of Chinese Medical Sciences (no. 2019–187-KY-02) and is registered with chictr.org (registration number ChiCTR2000031780). Abstract : Supplemental Digital Content is available in the text